How should pharma approach patient collaboration in the 2020s?
From the growing range of patient entities through to new possibilities stemming from technology and patient-generated data, pharma has more and more ways to innovate when it comes to collaborating with patients.
Now pharma needs to identify the ones that will really move the dial. “Clearly there is a shift from patient engagement as a nice-to-have, feel-good activity, to something which is more strategic,” says Vanessa Pott, Director, Patient Advocacy& Strategic Partnerships at Merck. “It’s really important for us to stay abreast of all the external trends.” To stay ahead of the curve in the coming...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news
How should pharma approach patient collaboration in the 2020s?
From the growing range of patient entities through to new possibilities stemming from technology and patient-generated data, pharma has more and more ways to innovate when it comes to collaborating with patients.
Now pharma needs to identify the ones that will really move the dial. “Clearly there is a shift from patient engagement as a nice-to-have, feel-good activity, to something which is more strategic,” says Vanessa Pott, Director, Patient Advocacy& Strategic Partnerships at Merck. “It’s really important for us to stay abreast of all the external trends.” To stay ahead of the curve in the coming...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news
How should pharma approach patient collaboration in the 2020s?
From the growing range of patient entities through to new possibilities stemming from technology and patient-generated data, pharma has more and more ways to innovate when it comes to collaborating with patients.
Now pharma needs to identify the ones that will move the dial commercially. “Clearly there is a shift from patient engagement as a nice-to-have, feel-good activity, to something which is more strategic,” says Vanessa Pott, Director, Patient Advocacy& Strategic Partnerships at Merck. “It’s really important for us to stay abreast of all the external trends.” To stay ahead of the curve in the ...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news
COVID-19 is accelerating digital transformation
No one in pharma needs to be told that COVID-19 is upending business as we know it. But in the face of this unprecedented change there is a great opportunity to adapt, improve and profit from new ways of working. And digital capabilities are the key to realising them, says Bertrand Bodson, Chief Digital Officer and Member of the Executive Board of Novartis in his keynote speech opening the eyeforpharma Virtual, a digital version of the Barcelona event, and available to delegates who can sign up for free athttps://virtual.eyeforpharma.com. Novartis is demonstrating how pharma can achieve rapid transformation and increas...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Leading the hunt for a COVID-19 vaccine
Paul Stoffels, J&J ’s Chief Scientific Officer, has given delegates ateyeforpharma ’s Barcelona Virtual conference exclusive insights into its rapid progress in the search for a vaccine to the COVID-19 virus. Speaking to Reuters News on day two of the five-day conference, Stoffels said J&J ’s potential vaccine, which has just been chosen as a lead candidate to help tackle the pandemic, could be ready for clinical trials as soon as early September with evidence of its safety and efficacy expected by the end of the year. This means that the first vaccinations could be given in the first quarter of 2021. ...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Leading the hunt for a COVID-19 vaccine
Paul Stoffels, J&J ’s Chief Scientific Officer, has given delegates at eyeforpharma’s Barcelona Virtual conference exclusive insights into its rapid progress in the search for a vaccine to the COVID-19 virus. Speaking to Reuters News on day two of the five-day conference, Stoffels said J&J ’s potential vaccine, which has just been chosen as a lead candidate to help tackle the pandemic, could be ready for clinical trials as soon as early September with evidence of its safety and efficacy expected by the end of the year. This means that the first vaccinations could be given in the first quarter of 2021. ...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application. Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain. As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn ' s& Colitis Foundation states, ...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application. Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain. As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn ' s& Colitis Foundation states, ...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application. Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain. As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn ' s& Colitis Foundation states, ...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Evolving HTA frameworks to accelerate innovation
Innovation in the cancer treatment space offers great promise, but even when approved by the European Medicines Agency (EMA) and other national regulatory bodies, patients can still face protracted delays in accessing new treatments.
Uncertainties in the evidence base for pioneering therapies can lead to delays from health technology assessment (HTA) agencies and payers in securing reimbursement.
To accelerate progress here, HTA frameworks must evolve, says Clare Hague, Therapy Area Market Access Lead, Hematology at Janssen EMEA, speaking ahead of the upcoming eyeforpharma Barcelona 2020 conference. “We need...
Source: EyeForPharma - March 14, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Evolving HTA frameworks to accelerate innovation
Innovation in the cancer treatment space offers great promise, but even when approved by the European Medicines Agency (EMA) and other national regulatory bodies, patients can still face protracted delays in accessing new treatments.
Uncertainties in the evidence base for pioneering therapies can lead to delays from health technology assessment (HTA) agencies and payers in securing reimbursement.
To accelerate progress here, HTA frameworks must evolve, says Clare Hague, Therapy Area Market Access Lead, Hematology at Janssen EMEA, speaking ahead of the upcoming eyeforpharma Barcelona 2020 conference. “We need...
Source: EyeForPharma - March 14, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
